Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
H + -K + -ATPase inhibitor. It inhibits the activity of H + -K + -ATPase in parietal cells of the stomach and blocks the final stage of hydrochloric acid secretion. This leads to a decrease in the level of basal and stimulated secretion, regardless of the nature of the stimulus. Due to a decrease in acid secretion, it reduces or normalizes the effect of acid on the esophagus in patients with reflux esophagitis.
Omeprazole has a bactericidal effect on Helicobacter pylori. Eradication of H. pylori with the simultaneous use of omeprazole and antibiotics allows you to quickly stop the symptoms of the disease, achieve a high degree of healing of the damaged mucosa and a stable long-term remission and reduce the likelihood of bleeding from the gastrointestinal tract.
When ingested quickly absorbed from the gastrointestinal tract. Penetrates into the parietal cells of the gastric mucosa. Binding to plasma proteins is about 95%, mainly with albumins. Biotransformatsya in the liver. It is excreted by the kidneys - 72-80%, with feces - about 20%. T 1/2 0.5-1 hour. In patients with chronic liver diseases, T 1/2 increases to 3 hours.
Peptic ulcer of the stomach and duodenum in the acute phase (including associated with Helicobacter pylori), reflux esophagitis, Zollinger-Ellison syndrome, erosive and ulcerative lesions of the stomach and duodenum associated with the intake of NSAIDs.
Individual. When administered orally, a single dose of 20-40 mg. The daily dose is 20-80 mg; frequency of application - 1-2 times / day. Duration of treatment is 2-8 weeks.
From the digestive system: rarely - nausea, diarrhea, constipation, abdominal pain, flatulence.
From the side of the central nervous system: rarely - headache, dizziness, weakness.
From the hemopoietic system: in some cases - anemia, eosinopenia, neutropenia, thrombocytopenia.
From the side of the urinary system: in some cases - hematuria, proteinuria.
From the musculoskeletal system: in some cases - arthralgia, muscle weakness, myalgia.
Allergic reactions: rarely - skin rash.
Chronic liver diseases (including in the anamnesis), children's age, hypersensitivity to omeprazole.
PREGNANCY AND LACTATION
Due to the lack of clinical experience, omeprazole is not recommended for use in pregnancy. If it is necessary to use during the lactation period, the question of stopping breastfeeding should be solved.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in chronic liver diseases (including in history).
APPLICATION FOR CHILDREN
Due to the lack of clinical experience, omeprazole is not recommended for use in children.
Before the start of therapy, it is necessary to exclude the possibility of the presence of a malignant process (especially with gastric ulcer), because Treatment with omeprazole can mask symptoms and delay correct diagnosis.
Against the background of the use of omeprazole, the results of laboratory studies of liver function and gastrin concentrations in the blood plasma may be distorted.
With simultaneous application, cases of the development of symptoms of toxic effects of benzodiazepines are described, which is associated with inhibition of the activity of CYP3A isoenzymes and, apparently, CYP2C9.
At simultaneous application with atrakury besylate the effects of atracurium besylate are prolonged.
With the simultaneous use of dicitrate with bismuth tricium, an undesirable increase in the absorption of bismuth is possible.
With simultaneous use with digoxin, a slight increase in the concentration of omeprazole in the blood plasma is possible.
With simultaneous use with disulfiram, a case of impaired consciousness and catatonia has been described; with indinavir - a decrease in the concentration of indinavir in blood plasma; with ketoconazole - a decrease in the absorption of ketoconazole.
With prolonged simultaneous use with clarithromycin, there is an increase in the concentrations of omeprazole and clarithromycin in the blood plasma.
The cases of decreasing the excretion of methotrexate from the body in patients receiving omeprazole are described.
With simultaneous application with theophylline, a slight increase in the clearance of theophylline is possible.
It is believed that with the simultaneous use of omeprazole in high doses and phenytoin, an increase in the concentration of phenytoin in the blood plasma is possible.
Cases of increasing the concentration of cyclosporine in the blood plasma are described when used simultaneously with cyclosporine.
At simultaneous application with erythromycin the case of increase in concentration of an omeprazole in a blood plasma is described, thus efficiency of an omeprazole decreased.